The FDA Needs A Conditional Approval System

BY JOSEPH GULFO – At the eteplirsen advisory committee meeting last week, the FDA panel voted seven to three against full approval and seven to six against accelerated approval for a drug for patients with a type of Duchenne Muscular Dystrophy.

Original: Forbes Real Time